(Editors' Note: This article covers a micro-cap stock. Please be aware of the risks associated with these stocks.)
Yesterday, Senesco Technologies (SNTI) reported positive results on its long-awaited cohort 3 in its phase 1b/2a trial for SNS01-T, an apoptosis-inducing cancer treatment being tested for multiple myeloma and diffuse large B-cell lymphoma [DLBCL]. Senesco followers have been awaiting this announcement for months now, and some investors expected a pop in SNTI shares if positive results were reported. They were indeed, though the stock actually reacted negatively, down $0.58 to $4.87 on volume twice above average, a drop of over 10%. What happened? First, some details on the trial and SNS01-T.
Senesco and SNS01-T
The main emphasis of Senesco is on "controlled...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|